Email: cspc@cspc.cn
Email: cspc@cspc.cn
August 30, 2022
The“Moxifloxacin Hydrochloride and Sodium Chloride Injection (250ml: 0.4g moxifloxacin and 2.0g sodium chloride)” (the “Product”) developed by CSPC has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.
Moxifloxacin is an 8-methoxy fluoroquinolone antibacterial drug with a broad antibacterial spectrum against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, acid-fast bacteria and atypical microorganisms (such as mycoplasma, chlamydia and legionella). The Product is indicated for treating the following infections in adults 18 years of age and older caused by susceptible bacteria: acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, skin and skin structure infections, complicated intra-abdominal infections and plague.
The approval of the Product will further enrich the Group’s product portfolio of anti-infective drugs.
